Diabetes drug shows promise for kidney and heart health in Non-Diabetic patients
NCT ID NCT07344922
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether dapagliflozin, a drug typically used for diabetes, can slow kidney decline, improve anemia, and support heart health in 100 adults with chronic kidney disease who do not have diabetes. Participants took either the drug or a placebo daily for 12 months alongside their usual care. The goal is to find a new way to manage these conditions without relying on lifelong medications beyond the study period.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Urology and Nephrology Center, Mansoura University
Al Mansurah, Dakahlia Governorate, 35511, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can less be more? testing transfusion limits in ECMO
- Aging kidneys under the microscope: could a simple test predict failure?
- A simple blood test trend may flag ICU patients at risk
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Rethinking anemia: does blood hemoglobin tell the whole story?